PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Articles
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Articles
  • Our team
  • Join us

An LLM is not (yet) a person skilled in the art (T 1193/23)

  • Sector: AI drug discovery
  • 20th May 2025
The EPO clarifies that an LLM interpretation of a technical term in a patent is not yet evidence of how a skilled person would interpret the term.
 

In the new AI-age, where Large Language Models (LLMs) like ChatGPT can generate sophisticated textual answers in seconds, the relevance of AI to the patent industry is an active area of debate. The recent EPO Board of Appeal in T 1193/23 specifically questioned the reliability of LLM-generated interpretations for technical terms within patent claims. Central to this case was the question of whether the output of LLMs, trained on everything on the internet, can serve as evidence of how a person skilled in the art would interpret a technical term in a patent claim

Legal background: The person skilled in the art

The concept of the person skilled in the art is fundamental to European patent law, particularly in the context of how claims are interpreted for sufficiency, novelty and inventive step analysis. According to the established case law of the Boards of Appeal, the “person skilled in the art” or “skilled person” is presumed to be a skilled practitioner in the relevant field of technology who has average knowledge and ability (average skilled person). This notional person is the addressee of a patent and serves as the standard against which novelty and inventive step are judged. 

The skilled person is also considered to be aware of what was common general knowledge (CGK) in the art at the relevant date. They are also presumed to have had access to everything in the “state of the art,” and to have had the means and capacity for routine work and experimentation which are normal for the field of technology in question. Traditionally, determining how the skilled person would understand technical terms in a patent has been a matter of expert evidence and established technical knowledge. 

Case background

The appeal case T 1193/23 concerned EP 3118356 owned by Rieter. The Opponent in the case was Saurer Spinning Solutions GmbH. The patent particularly related to improved safety mechanisms for operating rotor spinning machines. These machines, used in textile production, feature numerous rotors operating at extremely high speeds. The invention claimed a method for safely starting and stopping these rotors by checking bearing regulation or data connections before allowing operation. The main legal issue was whether the patent lacked novelty because all the features of the claim were allegedly disclosed in a prior art document. Critical to the decision was how the technical terms, such as “bearing regulation” should be interpreted in the context of the claimed invention. 

ChatGPT enters the proceedings

In a first for the EPO Boards of Appeal, the decision addressed the use of AI-generated content as evidence for claim interpretation. During oral proceedings, the Patentee verbally submitted responses from ChatGPT regarding the meaning of “bearing regulation” and other technical terms, arguing for a narrower definition of the terms than was proposed by the opponent. However, the Board of Appeal found that responses from ChatGPT alone could not establish an interpretation of the claims, but should be substantiated by expert evidence. The Board of Appeal went as far as to find the responses from ChatGPT to be “irrelevant, since the interpretation of the claim depends on the skilled person’s understanding”. As summarised in the headnote, the Board of Appeal concluded: 

“The general increase in the spread and use of chatbots based on language models (‘large language models’) and/or ‘artificial intelligence’ alone does not justify the assumption that a received answer – which is based on training data unknown to the user and can also depend sensitively on the context and the exact formulation of the question(s) – necessarily correctly reflects the expert’s understanding of the respective technical field (at the relevant time).” (r.1.1.1, emphasis added, machine translation)

With respect to the case in question, the Board of Appeal further noted that no proof other than the responses from ChatGPT were submitted to support the proposed definitions. Therefore, whilst the Board of Appeal found no absolute bar to the submission of evidence from LLMs, they nonetheless required that any such submissions be substantiated with additional proof. As the Board of Appeal went on to explain: “Evidence of how certain terms in the claim of a patent (or patent application) are interpreted by the person skilled in the art can be provided, for example, by appropriate technical literature. No such evidence has been submitted for the alleged different meanings of the above-mentioned terms in the relevant technical field” (r. 1.1.1). 

Is there a place for LLMs in claim interpretation?

The Board of Appeal based their decision on what it saw as three key limitations of AI systems like ChatGPT in the patent context. First, LLMs rely on training data unknown to the user. Second, the responses of LLMs depend sensitively on context and question formulation. Third, LLMs cannot be assumed to reflect actual expert understanding, especially at relevant points in time. 

The first point, regarding the training data for LLMs, is the weakest reason for rejecting their use for claim interpretation. Foundational LLM models such as ChatGPT, Claude and Gemini are trained on vast amounts of data extracted from the internet, books, and public documents. It is therefore fairly safe to assume that the LLM has access to the common general knowledge of the skilled person in most if not all technical fields. 

The Board of Appeal’s second and third arguments, i.e. that the response of an LLM will depend on the question and context, are more relevant. However, one could imagine a situation where these objections may be overcome. A LLM could, for example, be intelligently prompted to answer a question as if it was a skilled person in the field. In such a prompt, the LLM could be provided as context to the question, the EPO Guidelines and case law on what constitutes a skilled person and the identity of the technical field. The main issue with using LLM definitions for patent challenges, is knowing the cut-off date for the information on which the model is trained and has access to. Sometimes this information is given about a LLM, sometimes it is not. However, it is currently not possible to ask LLM providers to base answers on knowledge up until a certain date, given that this is not something most people have much use for. 

Turning back to the decision, a key problem for the Patentee in this case was the limited context they appeared to have provided in support of their submissions from ChatGPT. As the Board of Appeal observed, “the respondent did not submit the extensive, orally read, partly bullet-pointed responses [from ChatGPT] to the file in writing”. Details of the prompt and information given to ChatGPT appear to have been lacking. Having rejected the Patentee’s interpretation of the relevant terms, the Board of Appeal ultimately found that the main claim lacked novelty over the prior art. The Board of Appeal based their interpretation on technical analysis of the claim language in the context of the claim as a whole. The Board also refused all five auxiliary requests, finding that the additional claimed features in these requests lacked inventive step.

Use of the description to interpret the claims (G1/24)

Claim interpretation is a current hot topic at the EPO, whilst we await the decision of the Enlarged Board of Appeal on whether the description can and should be used to interpret the claims. I thought I would see how an LLM might interpret the term of contention in G 1/24. 

The case in G 1/24 centres on how the term “gathered” tobacco should be interpreted in a patent claim. The referring Board of Appeal decision in G 1/24 found that the term gathered has a specific meaning in the art. However, the description of the patent defines the term differently, specifically to include tobacco that is spiralled. Unfortunately for the patentee in G 1/24, this meant a product comprising spiralled tobacco was considered novelty destroying prior art for their claimed product. 

So how would an LLM have construed gathered tobacco? I asked Anthropic’s Claude, using the following prompt: 

See attached the guidelines and case law for what constitutes a person skilled in the art in European patent law. Answer the following question: You are a person skilled in the art in the field of the tobacco industry reading a patent related to a new type of electronic cigarette. Claim 1 is as follows: [Claim 1 of EP3076804B1]. How would you interpret the term “gathered” in this claim and does it include spiralled? 

 Claude supplied the following interpretation: 

As a person skilled in the art in the tobacco industry, I would interpret the term “gathered” in this patent claim to refer specifically to a manufacturing technique where a flat sheet of aerosol-forming material is pleated, folded, or crimped to create multiple folds bunched together, resulting in increased surface area within a confined cylindrical space. This is distinct from a “spiralled” configuration, which would involve winding or rolling the sheet in a helical manner around a central axis. These represent different, recognized manufacturing techniques in the tobacco industry with distinct structural outcomes, and the deliberate choice of “gathered” in the claim language would indicate to me that the patent is specifically claiming the pleated/folded configuration rather than a spiralled arrangement.

In a previous post, I explored how the rise of AI tools for patent drafting may increase the risk of the kind of problematic boilerplate language at issue in G 1/24. However, from above, it appears that LLMs can do a reasonably decent job at technical definitions when given the appropriate context. In fact, the use of LLMs to check the specification for overly broad and non-technical definitions might very well have saved the patent in G 1/24, as it may very well have identified the definition provided for “spiralled” as being at odds with the usual definition in the field. However, it is of course possible that the LLM has been influenced by all the commentary on the case…However, it is nonetheless clear that, in patent drafting and claim interpretation, the identity technical field is key. AI tools can therefore only be effective when they are informed of the appropriate technical context for their answers. 

Turning back to T 1193/23, it is notable that the Board of Appeal does not say that there is no place for evidence from LLMs in patent disputes, merely that the conclusions of an LLM need to be substantiated by additional supportive evidence. There are now plenty of LLM tools that will provide citations to substantiate their conclusions (which can be checked in order to establish their validity). As with any tool, to be most effective LLMs need to be used by the right person, in the right way for the right job.

Final thoughts

T 1193/23 marks an important first step for the EPO in addressing the role of AI in patent proceedings, establishing that LLM outputs alone cannot completely replace expert evidence. However, in my view LLMs will undoubtedly have a place in the patent industry. The business of patents involves debating the smallest nuances of meaning hidden in technical terminology, and LLMs represent an extraordinary resource for this task. Crucially, the Board of Appeal decision in T 1193/23 did not rule out the use of LLMs for claim interpretation, but merely indicates that any evidence based on the output of an LLM be supported and substantiated by additional evidence. 

To get the most out of LLMs in the context of patents, it is necessary to explicitly frame any queries within the specific technical field in question. Without this crucial contextual guidance, an LLM’s interpretation of highly specialised terms risks being too broad or misaligned. The nuanced and highly technical language of inventions demands an equally technical-field focused approach to the use of AI tools. 

This post is based on a previous article on IPKat.

Related insights...

Pitfalls of cell therapy manufacturing IP – A case study (T 0868/23)

  • 8th July 2025
In cell therapy the industry mantra is that the product is the process. However, this case illustrates that the best patent protection for a cell therapy is derived from the product. 

Non-reproducible commercial products are prior art (G1/23)

  • 7th July 2025
Is your product prior art if you disclose it before you file your patent, but without disclosing how it is made or what it is made from? The EBA answers “yes”.

The morality (and patentability) of inventions derived by immoral means (T 2510/18)

  • 25th June 2025
Should patents be granted for inventions born from unethical practices, even if they offer significant societal benefits?

How to read a biotech patent

  • 23rd June 2025
Learn how to quickly search for and extract key information from biotech patent documents.

EBA decides G1/24 on claim interpretation: The description should always be consulted

  • 19th June 2025
Understanding how patent claims are interpreted is crucial, and a recent EPO decision, G 1/24, provides new guidance: always consult the patent’s full description and drawings, not just the claims themselves.

Is it time for patent offices to enter the bioinformatic age?

  • 13th June 2025
In a world in which incalculable amounts of sophisticated sequence data is freely available, are the clunky processes necessary to input patent sequence data really fit-for-purpose?

Alexion’s Soliris sequence error saga (Alexion v Samsung Bioepis [2025] EWHC 1240)

  • 4th June 2025
Beware! The recent Samsung v Alexion UK High Court decision reveals that even a single-letter error in patent sequence data, coupled with vague descriptive language, can invalidate your claims and lead to costly legal battles.

Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy

  • 27th May 2025
Navigating European pharma and biotech patent litigation is more complex than ever, with ongoing debates on plausibility, UPC intricacies, claim interpretation, and divergent strategies for antibody inventions.

First UPC decision to tackle infringement and validity of second medical claims (Sanofi v Amgen, UPC_CFI_505/2024)

  • 19th May 2025
Understand the UPC’s first ruling on second medical use patents, which clarifies novelty and infringement standards but creates new hurdles for patentees, especially concerning “skinny labelling” and proving off-label use.

Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide)

  • 9th May 2025
Novo Nordisk’s recent setback with the European Patent Office (EPO) for semaglutide offers a critical lesson: even revolutionary drugs face patent rejection if their underlying composition, dose, and pH are deemed obvious in light of prior art, proving that commercial success alone cannot ensure patentability.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us